Susan Thornton, CEO of Cutaneous Lymphoma Foundation, discusses how the cutaneous lymphoma community may be impacted by potential COVID-19 vaccines.
Cutaneous lymphoma is a rare subtype of non-Hodgkin lymphoma that primarily affects the skin. Cutaneous lymphoma can originate in B-cells (i.e., cutaneous B-cell lymphoma); however, cutaneous T-cell lymphoma (CTCL) is more common.
Ms. Thornton noted that since COVID-19 vaccines and treatments target the immune system and CTCL is a cancer of the immune system, this is a potential concern for the patient community. Nevertheless, Ms. Thornton remains optimistic that COVID-19 treatment options available for cutaneous lymphoma patients will become available.
To learn more about cutaneous lymphoma and other rare cancers, visit checkrare.com/diseases/cancers/.